Identification of a cell-surface antigen selectively expressed on the natural killer cell by unknown
IDENTIFICATION  OF  A  CELL-SURFACE  ANTIGEN 
SELECTIVELY  EXPRESSED 
ON  THE  NATURAL  KILLER  CELL* 
BY L.  GLIMCHER,  F.  W.  SHEN,  AND H.  CANTORS 
(From the Department of Medicine, Harvard Medical School, Farber Cancer Center, Boston, 
Massachusetts  02115 and the Memorial Sloan-Kettering  Cancer Center, New York 10021) 
Spleen cells from certain  unimmunized  mouse strains  can kill  a  variety of 
murine leukemia virus (MuLV  ÷) syngeneic or allogeneic tumor cells. This type 
of 'natural killer' (NK) 1  activity has now been reported in many in vitro systems 
(1-15).  Several  studies,  mainly  by Kiessling  and  his  colleagues  (9-15),  have 
suggested (a) although NK cells are small lymphocytes, they cannot be classi- 
fied as mature T, B, or monocyte-macrophage cells using standard cell fractiona- 
tion procedures, (b) NK cells apparently do not bear Fc receptors on their surface 
and do not mediate antibody-dependent cellular cytotoxicity, (c) the presence of 
NK activity is controlled in part by genes within the H-2 complex, and (d) there 
is  a  correlation  between  the  presence  of in  vitro  NK  activity  and  in  vivo 
resistance to many lymphoid tumors. 
Despite this association between NK activity and resistance to tumor growth, 
it has not been possible to directly test their  role in the prevention  of tumor 
growth  in vivo or to establish  the  developmental relationship  of NK cells to 
other lymphoid subpopulations.  These  tests require  the  ability to  selectively 
deplete or purify this lymphocyte subclass from a heterogeneous cell population. 
We describe here the serologic definition of a  cell surface component which is 
selectively expressed on the surface of NK cells active against an MuLV  + tumor. 
Materials  and Methods 
Mice.  C57BL/6  (B6) mice  (Ly phenotype 1.2,2.2,3.2; H-2 b) and BALB/c mice (Ly phenotype 
1.2,2.2,3.2;  H-2 ~)  were  obtained  from  The  Jackson  Laboratory,  Bar  Harbor,  Maine  and  the 
congenic line, B6/Lyl.1, from Dr. E. A. Boyse. NZB, C3H/Bi, CBA/T6, BALB/c, C3H/An, DBA/2, 
and (BALB/c  ×  B6)FI (H-2 b~) were bred in our animal facilities from breeders supplied by The 
Jackson Laboratory. 
Antisera.  The production and use of anti-Lyl.2  (C3H anti-CE thymocyte antiserum),  anti- 
Ly2.2, and anti-Thyl.2 have been described previously (16). The Ly antisera were diluted 1:30 and 
absorbed twice with approximately 120 ×  10  e C3H thymus cells/ml to remove autoantibody. Anti- 
Thyl.2 was raised in (A/Thyl. 1 ×  AKR)F1 mice immunized with A-strain leukemic cells (ASLI); 
this serum had a  titer of 1:200 against LN cells and was used at a final dilution of 1:40. 
Tumor Cell Line.  The tumor used  as target cell  was  the  BALB/c  (H-2 ~) RLd 1 radiation- 
* Supported by National Institutes of Health Grants AI-12184 and AI-13600. 
Scholar of the Leukemia Society of America. 
1  Abbreviations  used in this paper: ASLI, A-strain leukemic cells; B6, C57BL/6; MULV, murine 
leukemia virus; NK, natural killer; NMS, normal mouse serum; a, anti. 
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induced leukemia obtained from Dr.  E.  A.  Boyse. These cells carry a  strong MuLV-associated 
antigen, X.1,  on their cell surface (17).  An in vitro line of RL~I  cells was established in our 
laboratory; the cells were grown in suspension in L15 medium supplemented with 15% tryptose 
phosphate broth and  15%  fetal calf serum and used as targets directly after harvesting. The 
P815  DBA/2 (H-2 ~) mastocytoma were also used after similar in vitro passage. 
Enrichment of Spleen T  Cells  by Nylon  Wool Columns.  Nylon wool columns were used as 
described previously (18), 80-85% of  the effluent cells were Ig-Thyl  +, and 1-6% were Ig+Thyl  -. 
Cytotoxicity  Assay.  We used the 5~Cr release method of Brunner et al.  (19) as modified by 
Canty and Wunderlich (20). Appropriate numbers of attacking cells were mixed with 5 x  104 ~Cr- 
labeled target cells and incubated 31/2-4 h in an atmosphere of 7% CO~. Cytotoxic activity for each 
test cell population was determined by the amount of 51Cr released from triplicate cultures of 
target cells during incubation compared with medium alone (control). Data were calculated by the 
following formula: 
cpm (test population) -  cpm (control) 
% lysis =  ×  100 
cpm maximum release (freeze-thaw) 
Standard errors for each triplicate culture were invariably less than 20%. 
Results 
Spontaneous Cytotoxicity  of B6 and NZB Lymphoid Cells to the RLdl Tumor 
(Table I).  B6 and NZB spleen cells express 'spontaneous' cytotoxicity against 
the RLd 1 (MuLV  +) but not against P815 (MuLV-). Levels of spleen cell cytotox- 
icity from B6 mice varied from experiment to experiment, ~anging from 15-40% 
at a  100:1 attacker/target ratio and averaging about 20-30%.  NK activity was 
consistently slightly higher in the NZB (25-40% lysis), a strain known to harbor 
MuLV. 
Various lymphoid organs in the B6 and NZB were analyzed for NK activity. 
These results are in agreement with previous findings (13): (a) spleen cells are 
most active; (b) lymph node and bone marrow cells are significantly less active; 
and (c) thymus cells have no activity. 
Surface Markers of the NK Cell 
THE  NK CELL IS NEITHER A T NOR A B LYMPHOCYTE  (FIG. 1).  Spleen cells from 
NZB and B6 mice that had passed through a nylon wool column (to deplete Ig  ÷ 
cells see Materials and Methods) expressed substantially increased NK activity 
compared  with  unpassed  cells.  Treatment of spleen  cells  with  anti-Thyl  + 
complement (C) also did not reduce NK activity compared with normal mouse 
serum (NMS) +  C-treated control spleen cells. These data indicate that the NK 
cell is not a typical mature T or B cell. 
NK  CELLS  EXPRESS  A  CELL  SURFACE  ANTIGEN  RECOGNIZED  BY  C3H  O~-CE 
('ANTI-LY1.2')  ANTISERUM  (FIG. 2).  To  determine  whether  the  NK  cells  ex- 
pressed Ly antigens, we treated nylon column-passed spleen cells with Ly sera 
÷  C. Treatment with either anti-Ly2.2 or anti-Thyl.2 +  C had no affect on NK 
activity. However, treatment with C3H anti-CE antiserum (anti-Lyl.2) abol- 
ished NK activity (Fig. 2). 
We were surprised by these results. Lyl antigens are thought to be expressed 
exclusively on T cells, and the NK cell bears no other T-cell markers (e.g., Thyl, 
Ly2). Therefore, we suspected that the C3H anti-CE antiserum contained anti- 
bodies to determinants other than Lyl.2 which are expressed on NK cells. To 
test this hypothesis, we examined the effects of C3H  aCE  serum  +  C  upon L.  GLIMCHER,  F.  W.  SHEN,  AND  H.  CANTOR 
TABLE  I 
Tissue Distribution of NK Activity against RL dl Tumor Target 
Cells 
Donor strain 
Percent lysis (100:1 A/T ratio)* 
RL d  P8155 
B6 
Spleen  22  +-- 2  0 
LN  12  _+  1.5  0 
BM  10 _+ 3  0 
Thymus  0  _+ 0,5  0 
NZB 
Spleen  34  _+ 2  0 
LN  14  _+ 3  0 
BM  10 _+  2.5  0 
Thymus  4  +_  1.5  0 
* See Materials and Methods for details of assay. 
$ In most cases net ~lCr release from mixtures of untreated cell popula- 
tions with P815 was less than that released from cultures containing 
P815 +  medium. 
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Fro.  1.  The effect of passage through a nylon column or treatment with anti-Thyl on NK 
activity.  NK  activity of spleen cells after (a)  passage through a  nylon column (A),  (b) 
treatment with anti-Thyl plus C  (©), and (c) treatment with NMS +  C  (O). B6 cell donors 
(left panel), NZB donors (right panel). 
spleen cells from a  congenic pair of B6 mouse strains differing only at the Lyl 
locus, B6/Lyl. 1, and B6(Lyl.2+). NK activity of spleen cells from both Lyl.1  + and 
Lyl.2  + congenic  B6 strains  were equally sensitive to the  C3H anti-CE  (anti- 
Lyl.2)  antiserum  (Fig.  3).  Hence  anti-NK  antibody  in  this  serum  was  not 
directed at the Lyl.2 antigen.  To confirm this point,  C3H aCE antisera  were 
absorbed with either B6 or B6/Lyl. 1 spleen cells; both absorptions removed aNK 
activity (Fig. 4). 
Absorption  of  C3HaCE  Sera  to  Produce  aNK  Sera  (Fig.  5).  We  then 
absorbed C3H anti-CE antiserum with BALB/c thymus and spleen cells (which 
are NK- and Lyl.2+). This absorption removed all anti-Lyl.2 activity, as tested 
by lysis of ~lCr-labeled  B6 lymph node cells,  but lei~  anti-NK  activity intact. 
This  absorbed  antiserum,  which  lysed  less  than  5%  of a  whole  spleen  cell 
population, therefore reacted with a surface component selectively expressed on 
NK cells. No loss of NK activity was noted after further absorption of aNK sera SEPARATION  OF  NATURAL  KILLER  CELLS 
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FIG.  2.  NK activity of nylon wool passed spleen cells treated with Ly antisera and anti- 
Thyl. The effect ofNMS + C alone (©), anti-Thyl + C (D), anti-Ly2 +  C (A), C3H anti-CE 
+  C (anti-Lyl.2) (0) upon the NK activity of spleen cells from NZB donors (left panel) and 
B6 donors (right panel) is shown. 
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FIG.  3.  The NK antigen is distinct from Lyl.2. NK activity of B6 spleen cells (0) and B6/ 
Lyl. 1 congenic spleen cells (©) after treatment with C3H anti-CE antiserum (anti-Lyl.2) or 
NMS.  C3HaCE antiserum  virtually eliminated NK activity from spleen cells of both Ly 
congenic strains. 
(1:30) with equal volumes of brain cells,  kidney cells,  or fibroblasts (data not 
shown). 
Strain Distribution  of aRLdl  NK Activity  and Susceptibility  to  aNK Anti- 
sera (Table II).  Spleen cells from a variety of inbred mouse strains were tested 
for spontaneous cytolytic activity against RL d 1 target cells. Cells from BALB/c 
mice and DBA/2 mice did not express significant NK activity. Spleen cells from 
B6,  (BALB/c  ×  B6)F~,  and  NZB mice produced substantial  NK activity; this 
activity was eliminated after treatment with C3H aCE sera. CBA/T6 and C3H/ 
Bi spleen cells also expressed significant levels of spontaneous lytic activity; this 
activity was resistant to treatment with C3H aCE sera  +  C. 
Production of Specific aNK Antiserum in (C3H  × BALB/c) F~ Mice Immu- 
nized to CE Spleen Cells (Table III).  To produce sera that would not require 
absorption with BALB/c cells to eliminate ~Lyl.2 activity, we immunized (C3H 
×  BALB/c)F1  mice  with  CE  spleen  cells  according  to  a  protocol  described 
previously (16). This serum did not contain aLyl.2 activity (BALB/c Ly pheno- 
type-Lyl.2, 2.2, 3.2), but retained anti-NK activity. Treatment of B6 spleen cells 
with this serum  +  C (a) did not result in detectable lysis above that seen with 
NMS +  C, but (b) virtually eliminated all spontaneous lysis vs. RLJ 1 targets. 
By contrast the sera had no effect on either B6 T-killer activity or plaque-form- 
ing cell activity (or TH activity, data not shown). Thus insertion of the BALB/c L.  GLIMCHER,  F.  W.  SHEN,  AND  H.  CANTOR 
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Fro.  4.  Removal of anti-NK activity after absorption of anti-CE serum with spleen cells 
from either B6 or B6/Lyl.1 spleen cells. NK activity of ny]on passed spleen cel]s treated 
with (a)  C3H  anti-CE serum that had been absorbed with  10  s B6 spleen cells/ml,  final 
dilution 1:40 (©), (b) C3H anti-CE absorbed with 10  s B6/Lyl.1 spleen cells/ml, final dilution 
1:40 (e), or (c) unabsorbed C3H anti-CE serum, final dilution 1:40  (()). 
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Fro.  5.  Removal of aLyl.2  activity and retention of NK  activity of C3HaCE  antisera. 
C3H anti-CE antiserum was absorbed with BALB/c thymocytes plus spleen cells (2.5 ×  108 
spleen cells + 2.5 x  108 thymocytes/ml of C3H aCE, final dilution 1:30). The resulting serum 
did not lyse significant numbers of B6 LN-T cells (left panel), but retained aNK activity 
(right panel). 
genotype into the host immunized with CE cells results in the production of an 
antiserum that reacts selectively with NK cells in the B6 mouse. 
Discussion 
Much recent immunologic research has focused on subclassifying cells of the 
immune system. Lymphoid cells have been divided on the basis of cell-surface 
markers into T cells, B cells, and 'null' cells involved in antibody-dependent cell- 
mediated cytotoxicity. T  cells have  been further  subdivided into three  major 
subclasses  on  the  basis  of selective  expression  of Ly gene  products: helper 
cells, cytotoxic/suppressor cells, and immature  cells whose immunoregulatory 
function is just beginning to be defined (21). 
NK cells can specifically damage certain types of tumor cells which express 
MuLV-associated antigens,  and this activity has been correlated with in vivo 
resistance to these tumors (12). However, it has not yet been possible to identify 
specific cell-surface markers on NK cells and thus directly test their role in the 6  SEPARATION  OF  NATURAL  KILLER  CELLS 
TABLE  II 
Strain Distribution of NK Activity and Susceptibility to ~ NK Sera 
Donor  strain*  (spleen  cells) 
Percent  lysis  of RL~  targets 
H-2 haplotype  NK  agn ÷ 
NMS  +  C  aNK  +  C 
B6  b  29  +_  3  0  + 
BALB/c  d  0  0 
(BALB/c  ×  B6)FI  bd  14  _+  1  3  -+  1  + 
NZB  d  36  _+  2  3  _+  1  + 
DBA/2  d  3  -+  1  5  _+  1 
CBA/T6  k  21  _+  1  19  _+  1.5  - 
C3H/An  k  6  _+  1  6  -+  1.5  - 
C3H/Bi  k  11  _+  2  10  _+  1.5  - 
*  Donors  4-8  wk  of age. 
S 60:1 attacker  target  ratio;  see  Materials  and  Methods  for  details  of procedures. 
TABLE  III 
The Effect of (C3H  × BALB/c)F1  aCE Sera Upon T-Killer Activity, PFC Activity, and 
NK Activity of B6 Spleen Cells 
SRBC-PFC (10~cells)  *  T-killer activity  (percent lysis vs.  P8155)  NK activity (percent lysis vs. RL  ~  i§) 
NMS + C  aNK +  C  Aft ratio  NMS + C  aNK  +  C  A/T ratio  NMS +  C  aNK  +  C 
390  420  10  44 +- 2  47 -+ 4  60  36 +  3.5  4 -+ 0.5 
5  31+-3.5  35-+  1  30  28-+  1  3-+0.5 
2.5  18-+  1  21_+ 2  15  19+-2  3-+ 1 
* Spleen cells from three B6 mice immunized with 107 SRBC six days earlier were treated with (C3H x  BALB)F~ aCE sera (final 
dilution  1:20)  or NMS + RC just before testing for aSRBC PFC according to a technique described previously  (22). 
$ Spleen cells from B6 mice given 3 x  l0  T  (BALB x B6)F~ spleen cells 9 days previously were treated with (C3H x BALB/c)F~ aCE 
sera (final dilution  1:20) or NTIS  +  RC, and then tested for eytolytic activity  against S~Cr-labeled P815 in a 4-h assay. 
§ Spleen cells from nonimmune  B6 mice were treated with (C3H  x  BALB/c)F,  aCE  sera (final dilution  1:20)  or NMS +  RC just 
before test for spontaneous  lysis of RLd 1 cells  (see Materials and Methods for protocol). 
prevention of tumors in vivo. Although NK cells have the morphology of small 
lymphocytes,  various  cell  fractionation  procedures  have  indicated  that  these 
cells  are  not  typical  T  cells,  B  cells,  Fc  receptor +  null  cells,  or  monocyte- 
macrophages  (13-15). 
Our experiments confirm previous findings that NK cells are Thyl- and Ig- 
(13-15). In addition, we have identified a cell-surface antigen that is selectively 
expressed on NK cells.  This surface component is recognized by C3H anti-CE 
thymocyte antiserum ('a Lyl.2'), but is distinct from the Lyl.2 surface antigen. 
We have produced an antiserum that reacts with NK cells but does not react 
with mature T or B  cells by absorbing C3H anti-CE antiserum with cells from 
NK-, Lyl.2 ÷ BALB/c mice. This absorption step was circumvented by inserting 
the BALB/c  genotype  into the recipient  immunized to CE cells,  i.e.,  (C3H  × 
BALB/c)  aCE  antiserum.  The  resultant  antiserum,  'aNK',  killed  <5%  of B6 
spleen cells, but selectively eliminated NK activity. 
Our experiments used relatively high attacker:target ratios in order to dem- 
onstrate significant NK activity. It is likely that these high ratios were required 
because NK cells represent less than 5% of the whole spleen cell population, and 
therefore these studies reflect true NK cell/target ratios of about 1:1-1:5. These 
considerations  indicate  that  the  NK  population  may  exert  powerful  cytolytic 
effects on appropriate tumor targets. L.  GLIMCHER,  F.  W.  SHEN,  AND  H.  CANTOR 
The C3H anti-CE thymocyte antiserum used in the first part of these experi- 
ments was made by injecting CE thymus cell suspensions into C3H mice. Since 
thymocytes do not  express  NK  activity,  it  is  somewhat surprising  that  this 
antiserum contained anti-NK antibody. There are several possible explanations: 
(a) NK cells may be present in CE thymus, albeit in very small numbers. The 
repeated injections of large numbers of CE thymocytes (2-5 x  107/wk, 10-15 wk) 
necessary to produce aLyl.2 antiserum might also be sufficient to raise antibody 
against NK cells even though our functional assay does not detect significant 
NK activity.  (b) The NK antigen  in the thymus preparations  may reflect the 
presence  of contaminating  NK  cells  from nonthymus  tissue,  including  para- 
thymic lymph node cells or circulating blood lymphocytes. (c) The thymus may 
contain NK cell precursors which bear the NK antigen, but do not yet express 
NK cell activity. (d) The existence of mature NK cells in thymus may be masked 
by thymic suppressor cells. Our data does not help select among these possibili- 
ties.  Nonetheless,  for whatever reason,  C3H  aCE  thymocyte serum contains 
high titers of aNK antibodies. 
Inasmuch  as  C3H  mice  produce  anti-NK  antibody,  which  eliminates  NK 
activity from spleen cells of at least two strains, B6 and NZB, but does not affect 
NK activity of spleen cells from C3H/Bi or CBA/T6 mice, it is likely that the NK 
alloantigen is expressed either as two or more alleles including 'NK-C3H' and 
'NK-B6' or possibly as a  single allelic product that is not expressed by C3H or 
CBA mice. In either case, the present studies demonstrate that at least some 
mouse strains  possess NK cells that can be selectively eliminated by the sera 
described in this report.  The fact that the NK antigen is not expressed on the 
surface of mature T cells, B cells, kidney cells, or brain cells suggests that it falls 
into an increasingly useful category of cell-surface differentiation components 
that are selectively expressed on cells at particular phases of their differentia- 
tive history. The contribution of the NK cell-surface component defined in these 
studies to NK activity has not been extensively investigated, although prelimi- 
nary experiments indicate the presence of aNK sera does not inhibit NK cell- 
mediated lysis. 
The biologic significance of the NK cell is presently incompletely understood. 
Previous work has shown that  (a)  there  is a  correlation between in vitro NK 
activity and in vivo tumor resistance  (12),  and (b)  there is a  low incidence of 
RNA tumors in nude  (congenital  athymic) mice which have high NK activity 
(13,  14).  For these reasons,  it is possible that the NK cell may play a  role in 
immunosurveillance against tumors. Selective removal of NK cells from spleen 
and  bone  marrow  cells  before  adoptive  transfer  to  irradiated  hosts  is  now 
possible and will permit direct testing of this hypothesis. 
Summary 
We have studied the cell-surface phenotype of natural killer (NK) cells of NZB 
and  B6 mice which react to an  MuLV  + lymphoid tumor.  (a)  NK cells do not 
express  Thyl,  Ly2,  or  Ig  surface  markers.  (b)  NK  cells  express  an  antigen 
recognized by C3H anti-CE  antiserum  ('anti-Lyl.2  antiserum').  Inasmuch  as 
NK activity of spleen cells from B6 and B6/Lyl.1 congenic strains  were both 
equally sensitive to C3H anti-CE  antiserum,  the NK antigen  is distinct from 
Lyl.2.  This  point  was  confirmed  by the  observation  that  aNK  activity was SEPARATION  OF  NATURAL  KILLER  CELLS 
removed by absorption of C3H anti-CE antiserum with spleen cells from either 
B6 or B6/Lyl.1 congenic strains. 
Absorption  of C3H  aCE  serum  with  BALB/c  thymocytes  and  spleen  cells 
(which are Lyl.2+NK -) removed anti-Lyl.2  activity and  left anti-NK  activity 
intact.  This  absorption  step  could  be  circumvented  by  inserting  the  BALB/c 
genotype into the recipient immunized to CE cells (i.e., (C3H x  BALB/c)F, aCE 
spleen  cells).  This  antiserum,  provisionally  termed  'anti-NK',  defines  a  new 
subclass of lymphocytes which may play a  central  role in the immunosurveil- 
lance against tumors. 
We thank Ms. Joan Hugenberger and Ms. Laila Boudreau for skilled technical assistance and 
Ms. Debra Garrigan for secretarial help. 
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